Too Potent, Too Cheap? Why Cannabis Policy Needs a Rethink on Price and Potency
Cannabis legalization without intelligent regulation creates incentives for increasingly potent and inexpensive THC products that may elevate public health risks.
High-THC cannabis concentrates are associated with increased rates of cannabis use disorder, psychosis risk, and emergency room visits, particularly among adolescents and frequent users.
Research suggests price controls and potency caps influence different outcomes. Higher prices reduce overall use, while potency limits reduce harm from extreme THC exposure.
Smart cannabis regulation is not prohibition. It is a harm-reduction strategy designed to support informed adult use while minimizing predictable risks.
Potency-based taxation, transparent labeling, and education standards could help create a more sustainable and medically responsible cannabis industry.
The future of cannabis policy will depend less on ideology and more on whether regulators are willing to follow emerging evidence.
A new study published in Addiction suggests that cannabis pricing and potency regulations can significantly reduce problematic use and cannabis-related harms. The evidence points toward a balanced model where moderate taxation and sensible potency limits work together to reduce risk without dismantling legal access.
The case for smarter cannabis regulation is not about prohibition. It is about precision.
Legalization has changed the cannabis landscape dramatically, but legalization alone was never going to solve every problem. As markets expand and competition intensifies, the industry has drifted toward an increasingly predictable outcome: stronger products sold at lower prices. In many legal states, ultra-high THC flower and concentrates are now cheaper and more accessible than ever before.
That combination matters.
A new modeling study published in Addiction, titled “Estimating and comparing the effects of price‐ and potency‐based policies on cannabis use and related harms,” explored how different regulatory approaches might shape real-world cannabis consumption and public health outcomes. The findings suggest policymakers already have effective tools available. The challenge is using them intelligently.
“Cannabis legalization without intelligent regulation creates a market that rewards maximum intoxication.”
The study examined how cannabis use patterns shifted under different hypothetical policy conditions. Researchers found that raising prices generally reduced overall cannabis consumption, while potency caps specifically reduced harms associated with high-THC exposure. The strongest outcomes emerged when both strategies were combined.
That distinction is important because cannabis harm is not solely about whether people consume cannabis. It is increasingly about what they are consuming and how concentrated those products have become.
According to research published in The Lancet Psychiatry, daily use of high-potency cannabis is associated with significantly increased odds of psychotic disorders, especially among genetically or psychologically vulnerable individuals (https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(19)30048-3/fulltext). Additional evidence from the National Institutes of Health has linked frequent high-potency cannabis use with greater risk of cannabis use disorder and mental health complications (https://nida.nih.gov/publications/research-reports/marijuana/there-link-between-marijuana-use-psychiatric-disorders).
“THC concentration changes the pharmacological experience. It is not merely a stronger version of the same product.”
Modern concentrates routinely exceed 80% THC. Some vape cartridges approach 90%. Compare that to the roughly 3–5% THC cannabis commonly available in the 1970s or even the 10–15% flower many adults remember from the early medical cannabis era. The human endocannabinoid system evolved to respond to cannabinoids gradually, not necessarily through repeated exposure to hyper-concentrated extracts delivered in seconds.
That does not make concentrates inherently evil. But pretending potency is irrelevant ignores both pharmacology and emerging epidemiological evidence.
“High-potency cannabis does not create risk in every user. It increases risk probability across populations.”
That distinction matters because public health policy is almost always probabilistic. We regulate alcohol differently based on alcohol-by-volume content. We regulate prescription medications differently based on potency and abuse potential. Cannabis is beginning to demand the same level of nuance.
The study’s findings support a growing argument for potency-based taxation rather than simplistic weight-based taxes. Canada has already experimented with THC-linked taxation structures, recognizing that 100 milligrams of THC is not equivalent across all product formats or user experiences. Research published in the International Journal of Drug Policy has similarly suggested that THC-based pricing models may reduce harmful consumption patterns while preserving legal market participation (https://www.sciencedirect.com/science/article/pii/S0955395921001168).
“Regulation works best when it shapes behavior without eliminating autonomy.”
That means the goal should not be eliminating access to high-potency products altogether. The goal should be creating friction around excessive potency while preserving informed adult choice. Tiered potency categories, escalating taxes on ultra-high THC products, mandatory cannabinoid labeling, and better retail education standards are all practical policy tools.
Education may be one of the most overlooked pieces of the equation.
Many consumers still have little understanding of dosing, cannabinoid ratios, or how concentrates differ from traditional flower. Research from the Centers for Disease Control and Prevention has noted that higher THC levels may increase the likelihood of adverse psychological reactions, particularly among inexperienced users (https://www.cdc.gov/cannabis/health-effects/index.html).
“Consumers deserve to know not only what they are buying, but what it is likely to do.”
That becomes even more important as the legal industry matures. The cannabis movement spent decades fighting stigma, criminalization, and misinformation. But legitimacy brings responsibility. A mature industry cannot simply celebrate legalization while ignoring the unintended consequences of unlimited potency escalation.
Legal cannabis is a major cultural and medical victory. Still, legalization is not the finish line. It is the beginning of a more complicated conversation about how to balance freedom, safety, public health, and commercial incentives.
The Addiction study makes one thing increasingly difficult to deny: smarter regulation is not anti-cannabis. In many ways, it may be the very thing that protects the long-term credibility and sustainability of the industry itself.
Research suggests frequent use of high-THC cannabis products may increase the likelihood of psychosis, anxiety, and cannabis use disorder in vulnerable individuals. Risk appears to rise as THC concentration and frequency of use increase.
Potency-based taxation applies taxes according to THC content rather than product weight or package size. The goal is to discourage excessive THC concentrations while preserving access to lower-potency products and supporting safer consumption patterns.
Matthew Myro Rothman is Chief Science Officer and VP of Marketing at EM2P2 and CannaLnx, where he helps bridge medical cannabis, healthcare infrastructure, patient education, and emerging technology. A lifelong musician, writer, philosopher, and cannabis science expert, Matthew spent more than 15 years working in cultivation, consulting, and medical cannabis operations throughout California before returning to Ohio to help shape the future of intelligent cannabis medicine. He holds a graduate degree in Philosophy, Cosmology, and Consciousness from California Institute of Integral Studies and writes extensively on cannabis science, consciousness, wellness, and human performance.
Please note: You are not currently logged in. Only members can contribute comments. If you would like to contribute click the button below.
